Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development
Download this complimentary Expert Insights eBook today!
bispecific antibodies
Dren Bio, Novartis to Develop Bispecific Cancer Antibodies
US biopharmaceutical company Dren Bio, a developer of novel antibody therapeutics, has entered into a collaboration with Novartis Pharma, a subsidiary of Novartis. The collaboration will focus on the discovery and development of therapeutic bispecific antibodies for cancer using Dren Bio’s proprietary targeted myeloid engager and phagocytosis platform.
J&J Acquires Rights to Numab's Bispecific Antibody NM26
US healthcare giant Johnson & Johnson (J&J) agreed to acquire Yellow Jersey Therapeutics (YJT) from biotechnology company Numab Therapeutics in an all-cash transaction valued at approximately $1.25 billion, giving it worldwide rights to the novel, investigational bispecific antibody NM26.
